Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Immune Thrombocytopenia: full-pipeline trial registry
1 of 5 indexed Primary Immune Thrombocytopenia trials are currently recruiting.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Primary Immune Thrombocytopenia: 5 US clinical trials tracked, 1 recruiting.
Primary Immune Thrombocytopenia is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is argenx, running 2 of these trials.
Enrollment posture brief
Registry condition primary-immune-thrombocytopenia
OPEN 1 | RECR 20% | LATE 3 | EARLY 2 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Primary Immune Thrombocytopenia lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Immune Thrombocytopenia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Immune Thrombocytopenia is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Primary Immune Thrombocytopenia research.
argenx accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Primary Immune Thrombocytopenia enrolment sits around 131 participants.
Median target enrolment is 131 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Primary Immune Thrombocytopenia research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
Pfizer
NCT05070845
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
argenx
NCT04812925
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
Novartis Pharmaceuticals
NCT05653219
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
argenx
NCT04188379
A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
Takeda
NCT04278924
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Immune Thrombocytopenia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Immune Thrombocytopenia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Immune Thrombocytopenia page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Primary Immune Thrombocytopenia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- argenx sponsors the most Primary Immune Thrombocytopenia trials on record, review their full trial history before evaluating a specific study. See argenx's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Immune Thrombocytopenia condition card totals 5 registered trials; most-linked intervention Placebo; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.